Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHE:002399)

Market Cap	13.85B -2.2%
Revenue (ttm)	5.42B +2.1%
Net Income	380.47M -41.3%
EPS	0.26 -41.3%
Shares Out	1.47B
PE Ratio	40.11
Forward PE	17.93
Dividend	0.25 (2.43%)
Ex-Dividend Date	Jul 7, 2025

Volume	1,859,800
Average Volume	4,318,608
Open	10.30
Previous Close	10.40
Day's Range	10.18 - 10.39
52-Week Range	10.03 - 14.34
Beta	0.45
RSI	37.32
Earnings Date	Apr 29, 2026

About SHE:002399

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. The company operates through four segments: Finished dose pharmaceutical products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization, and Others. Its pharmaceutical products consist of finished dose pharmaceutical products, which primarily include enoxaparin sodium injection; API products, including heparin sodium A...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 2,150
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002399

Financial Performance

In 2025, SHE:002399's revenue was 5.48 billion, an increase of 3.75% compared to the previous year's 5.28 billion. Earnings were 349.49 million, a decrease of -45.96%.